Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 144-148

  Morrissey, Ian ^a   Tillotson, Glenn ^b  

^a GR Micro Ltd   (United Kingdom)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Acute exacerbation of chronic bronchitis; Community acquired pneumonia; Fluoroquinolones; Fluoroquinolones resistance; Respiratory tract infections

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CHRONIC BRONCHITIS; COMMUNICABLE DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HUMAN; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; NAPHTHYRIDINES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 1242352917     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh092     Document Type: Review

References (69)

1. King, A., May, J., French, G. et al. (2000). Comparative in vitro activity of gemifloxacin. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 1-12.
2. McCloskey, L., Moore, T., Niconovich, N. et al. (2000). In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 13-21.
3. Ball, P., File, T. M., Twynholm, M. et al. (2001). Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. International Journal of Antimicrobial Agents 18, 19-27.
4. Ball, P., Wilson, R., Mandell, L. et al. (2001). Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. Journal of Chemotherapy 13, 288-98.
5. File, T. M., Jr, Schlemmer, B., Garau, J. et al. (2001). Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. Journal of Antimicrobial Chemotherapy 48, 67-74.
6. United States Food and Drug Administration. (2003). [Online.] http://www.fda.gov/cder/foi/appletter/2003/21158se1-001ltr.pdf (8 August 2003, date last accessed).
7. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
8. Felmingham, D., Reinert, R. R., Hirakata, Y. et al. (2002). Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 25-37.
9. Hoban, D. J., Doern, G. V., Fluit, A. C. et al. (2001). Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clinical Infectious Diseases 32, Suppl. 2, S81-93.
10. Niederman, M. S. (2001). Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Medical Clinics of North America 85, 1493-509.
11. Niederman, M. S., Mandell, L. A., Anzueto, A. et al. (2001). Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine 163, 1730-54.
12. Bryskier, A. (1999). Respiratory fluoroquinolones: myth or reality? Current Opinion in Anti-infective Investigational Drugs 1, 413-7.
13. Jacobs, M. R., Felmingham, D., Appelbaum, P. C. et al. (2003). The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Journal of Antimicrobial Chemotherapy 52, 229-46.
14. Jones, R. N., Rubino, C. M., Bhavnani, S. M. et al. (2003). Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrobial Agents and Chemotherapy 47, 292-6.
15. Koeth, L. M., Jacobs, M. R., Bajaksouzian, S. et al. (2002). Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. International Journal of Antimicrobial Agents 19, 33-7.
16. Heaton, V. J., Goldsmith, C. E., Ambler, J. E. et al. (1999). Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrobial Agents and Chemotherapy 43, 2998-3000.
17. Jorgensen, J. H., Weigel, L. M., Swenson, J. M. et al. (2000). Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 44, 2962-8.
18. Reinert, R. R., Al-Lahham, A., Lutticken, R. et al. (2002). Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. Journal of Antimicrobial Chemotherapy 49, 1015-8.
19. Yague, G., Morris, J. E., Pan, X. S. et al. (2002). Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrobial Agents and Chemotherapy 46, 413-9.
20. Heaton, V. J., Ambler, J. E. & Fisher, L. M. (2000). Potent anti-pneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrobial Agents and Chemotherapy 44, 3112-7.
21. Morrissey, I. & George, J. T. (2000). Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 101-6.
22. Ambrose, P. G., Grasela, D. M., Grasela, T. H. et al. (2001). Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrobial Agents and Chemotherapy 45, 2793-7.
23. Mattoes, H. M., Banevicius, M., Li, D. et al. (2001). Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 45, 2092-7.
24. Lacy, M. K., Lu, W., Xu, X. et al. (1999). Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrobial Agents and Chemotherapy 43, 672-7.
25. Zhanel, G. G., Roberts, D., Waltky, A. et al. (2002). Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 49, 807-12.
26. Morrissey, I. & George, J. T. (2000). Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 107-10.
27. Cottagnoud, P., Acosta, F., Cottagnoud, M. et al. (2002). Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrobial Agents and Chemotherapy 46, 1607-9.
28. Garcia-Olmos, M., Parra, A., Garcia-Calvo, G. et al. (2003). Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility. International Journal of Antimicrobial Agents 21, 568-73.
29. Hoban, D. J., Bouchillon, S. K., Karlowsky, J. A. et al. (2000). A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group. Antimicrobial Agents and Chemotherapy 44, 3008-11.
30. Ho, P. L., Yung, R. W., Tsang, D. N. et al. (2001). Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. Journal of Antimicrobial Chemotherapy 48, 659-65.
31. Ho, P. L., Que, T. L., Tsang, D. N. et al. (1999). Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrobial Agents and Chemotherapy 43, 1310-3.
32. Ho, P. L., Yam, W. C., Cheung, T. K. et al. (2001). Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerging Infectious Diseases 7, 906-8.
33. Morrissey, I., Farrell, D. J., Bakker, S. et al. (2003). Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong. Antimicrobial Agents and Chemotherapy 47, 1433-5.
34. Alou, L., Ramirez, M., Garcia-Rey, C. et al. (2001). Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrobial Agents and Chemotherapy 45, 2955-7.
35. McGee, L., Goldsmith, C. E. & Klugman, K. P. (2002). Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. Journal of Antimicrobial Chemotherapy 49, 173-6.
36. Davies, T. A., Goldschmidt, R., Pfleger, S. et al. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). Journal of Antimicrobial Chemotherapy 52, 168-75.
37. Johnson, C. N., Benjamin, W. H., Jr, Moser, S. A. et al. (2003). Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. Journal of Clinical Microbiology 41, 2458-64.
38. Weiss, K., Restieri, C., Gauthier, R. et al. (2001). A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 33, 517-22.
39. Ball, A. P. & Tillotson, G. S. (1995). Lower respiratory tract infection therapy - the role of ciprofloxacin. Journal of International Medical Research 23, 315-27.
40. Fogarty, C., Goldschmidt, R. & Bush, K. (2000). Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clinical Infectious Diseases 31, 613-5.
41. Fogarty, C. M., Greenberg, R. N., Dunbar, L. et al. (2001). Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clinical Therapeutics 23, 425-39.
42. Empey, P. E., Jennings, H. R., Thornton, A. C. et al. (2001). Levofloxacin failure in a patient with pneumococcal pneumonia. Annals of Pharmacotherapy 35, 687-90.
43. Urban, C., Rahman, N., Zhao, X. et al. (2001). Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. Journal of Infectious Diseases 184, 794-8.
44. Kays, M. B., Smith, D. W., Wack, M. E. et al. (2002). Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22, 395-99.
45. Davidson, R., Cavalcanti, R., Brunton, J. L. et al. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747-50.
46. Anderson, K. B., Tan, J. S., File, T. M. et al. (2003). Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clinical Infectious Diseases 37, 376-81.
47. Scheld, W. M. (2003). Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerging Infectious Diseases 9, 1-9.
48. Pérez-Trallero, E., Marimon, J. M., Iglesias, L. et al. (2003). Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerging Infectious Diseases 9, 1159-62.
49. Ball, P. (1995). Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108, 43S-52S.
50. Brooks, I., Gooch, W. M., III, Jenkins, S. G. et al. (2000). Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Annals of Otology, Rhinology and Laryngology 182, 2-20.
51. LaForce, F. M. (1992). Antibacterial therapy for lower respiratory tract infections in adults: a review. Clinical Infectious Diseases 14, Suppl. 2, S233-237.
52. Hoban, D. & Felmingham, D. (2002). The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 49-59.
53. Zhanel, G. G., Palatnick, L., Nichol, K. A. et al. (2003). Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrobial Agents and Chemotherapy 47, 1875-81.
54. Doern, G. V., Jones, R. N., Pfaller, M. A. et al. (1999). Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrobial Agents and Chemotherapy 43, 385-9.
55. Felmingham, D. (2002). The need for antimicrobial resistance surveillance. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 1-7.
56. Barriere, S. L. & Hindler, J. A. (1993). Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease. Annals of Pharmacotherapy 27, 309-10.
57. Gould, I. M., Forbes, K. J. & Gordon, G. S. (1994). Quinolone resistant Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 33, 187-8.
58. Campos, J., Roman, F., Georgiou, M. et al. (1996). Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. Journal of Infectious Diseases 174, 1345-7.
59. Vila, J., Ruiz, J., Sanchez, F. et al. (1999). Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrobial Agents and Chemotherapy 43, 161-2.
60. Bootsma, H. J., Troelstra, A., van Veen-Rutgers, A. et al. (1997). Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands. Journal of Antimicrobial Chemotherapy 39, 292-3.
61. Nazir, J., Urban, C., Mariano, N. et al. (2002). Levofloxacin resistant Haemophilus influenzae in a long term care facility. In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract C2-647, p. 696. American Society for Microbiology, Washington, DC, USA.
62. Biedenbach, D. J. & Jones, R. N. (2003). Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease 46, 55-61.
63. Davies, T. A., Jacobs, M. R. & Appelbaum, P. C. (1999). Activity of gemifloxacin (SB-265805) compared with other quinolones against quinolone-resistant Haemophilus influenzae. In Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1499, p. 1267. American Society for Microbiology, Washington, DC, USA.
64. Morrissey, I. & George, J. T. (2000). Activity of gemifloxacin and other fluoroquinolones against DNA gyrase and topoisomerase IV from Haemophilus influenzae. In Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 749, p. 781. American Society for Microbiology, Washington, DC, USA.
65. Boswell, F. J., Andrews, J. M., Jevons, G. et al. (2002). Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. Journal of Antimicrobial Chemotherapy 50, 495-502.
66. Portnoy, Y. A., Vostrov, S. N., Lubenko, I. Y. et al. (2002). Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. International Journal of Antimicrobial Agents 20, 201-5.
67. Berry, V., Page, R., Satterfield, J. et al. (2000). Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. Journal of Antimicrobial Chemotherapy 45, Suppl. S1, 79-85.
68. Berry, V., Page, R., Satterfield, J. et al. (1999). Comparative efficacy of gemifloxacin (SB-265805) against experimental respiratory tract infection in rats caused by ciprofloxacin-resistant strains of S. pneumoniae and H. influenzae. In Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1548, p. 1576. American Society for Microbiology, Washington, DC, USA.
69. Read, R. C., Morrissey, I. & Ambler, J. E. (2002). Clinician's Manual on Respiratory Tract Infections and Fluoroquinolones, 2nd edn. Science Press, London, UK.